Regulating Pharmaceutical Prices in the European Union

Roland Attila Csizmazia

MPRA Paper from University Library of Munich, Germany

Abstract: This case study aims to provide a better understanding of the necessity for regulation in the market for pharmaceuticals and to reveal the impacts of parallel trades in the European Union and how they may affect markets in the future. The pharmaceutical industry up to now has largely been regulated. Although the EU is a single market, it still has variable prices for pharmaceuticals. Consequently, the price gap and other EU-specific factors have created a great environment for parallel trades. The author has confined this study to the price regulations inside the EU before the enlargement in 2004.

Keywords: Regulation; pharmaceutical market; European Union; parallel trade (search for similar items in EconPapers)
JEL-codes: D40 (search for similar items in EconPapers)
Date: 2013-12-01
New Economics Papers: this item is included in nep-com, nep-eur, nep-ind and nep-reg
References: View complete reference list from CitEc
Citations: Track citations by RSS feed

Published in International Journal of Business Knowledge and Innovation in Practice 1.1(2013): pp. 8-20

Downloads: (external link)
https://mpra.ub.uni-muenchen.de/52945/1/IJBKIP-01- ... cal_Prices_in_EU.pdf original version (application/pdf)

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:pra:mprapa:52945

Access Statistics for this paper

More papers in MPRA Paper from University Library of Munich, Germany Ludwigstraße 33, D-80539 Munich, Germany. Contact information at EDIRC.
Bibliographic data for series maintained by Joachim Winter ().